MedTrace Logo

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)

NCT02513732 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-05-13

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.

Conditions

Interventions

DEVICE

XIENCE Xpedition 2.25 mm stent

Patients receiving XIENCE Xpedition 2.25 mm stent

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Ken Kozuma, MD · Teikyo University Hospital, Tokyo

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02513732 on ClinicalTrials.gov